1-methyl-4-phenylpyridinium has been researched along with Parkinsonian Disorders in 92 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 48 (52.17) | 29.6817 |
| 2010's | 33 (35.87) | 24.3611 |
| 2020's | 11 (11.96) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, H; Jung, YJ; Oh, E | 1 |
| Chen, Y; Li, L; Tang, J; Yuan, L | 1 |
| Geng, Y; Li, Y; Qin, J; Song, Q; Wang, L | 1 |
| Ba, RQ; Fan, XJ; Huang, BG; Jin, GL; Liu, J; Liu, MW; Yang, JS | 1 |
| Qian, SX; Shen, YF; Wang, YP; Xu, CY; Zhu, ZY | 1 |
| Arslan, ME; Cacciatore, I; Di Stefano, A; Küçükdoğru, R; Mardinoğlu, A; Sönmez, E; Tozlu, ÖÖ; Türkez, H | 1 |
| Cao, F; Chen, P; Duan, JA; Guo, S; Liu, C; Liu, J; Qian, B; Qian, D; Wang, Y; Xu, C; Yan, Y; Zhang, F; Zhang, X | 1 |
| Dong, YK; He, CC; Huang, J; Huang, XM; Liao, JX; Tang, YW; Tian, JY; Wu, D; Zhang, Q; Zhu, JL | 1 |
| Han, C; He, T; Waddington, JL; Wan, C; Wang, M; Zhen, X; Zhu, K | 1 |
| Balboni, G; Mao, J; Peng, Y; Shao, N; Xia, Y; Xu, Y; Yang, Y; Zhi, F | 1 |
| Hu, L; Li, Q; Yan, W; Zhang, Y; Zhou, H | 1 |
| Chen, Y; Huang, X; Jiang, Y; Sun, C; Yang, Y | 1 |
| Cheng, Y; Lee, SM; Luo, D; Rong, J; Zhao, J | 1 |
| Chen, S; Liu, A; Tang, L; Wan, J; Xiong, Y; Zhang, S; Zheng, N | 1 |
| Jiang, Y; Li, J; Li, TQ; Zhang, HY | 1 |
| Chen, Y; Geng, L; Liu, W; Zhang, T | 1 |
| Liu, Y; Lu, Z | 1 |
| Baghi, M; Ghaedi, K; Kiani-Esfahani, A; Nasr-Esfahani, MH; Rostamian Delavar, M; Safaeinejad, Z | 1 |
| Capps, J; Virga, DM; Vohra, BPS | 1 |
| Chang, J; Chen, J; Yu, H; Zhang, XL | 1 |
| Ansah, T; Channon, KM; Charlton, C; Gangula, PR; Hale, A; Kalpana, R; Sampath, C; Srinivasan, S | 1 |
| Ganguly, A; Lee, D; Schultz, BJ; Wiemerslage, L | 1 |
| Li, WW; Lu, CZ; Zhu, M | 1 |
| Choi, JW; Park, KS; Song, MY | 1 |
| Freestone, PS; Glass, M; Hunter, MR; Lee, SM; Lipski, J; Yee, AG | 1 |
| Haobam, R; Kaidery, NA; Mohanakumar, KP; Tripathy, D | 1 |
| He, L; Hong, X; Li, J; Wang, X; Zhu, G | 1 |
| Li, Y; Yang, C; Zhang, J | 1 |
| Aguirre-Vidal, Y; Anaya-Ramos, L; Baron-Flores, V; Monroy-Noyola, A; Montes, S; Ríos, C; Teiber, J; Tristan-López, L | 1 |
| Lavalley, N; McFerrin, M; Slone, SR; Wang, B; Yacoubian, TA | 1 |
| Guo, H; Hu, L; Li, M; Liu, Q; Shi, F; Yu, B | 1 |
| Deng, X; Hu, X; Hu, Y; Huang, B; Le, W; Lei, X; Li, H; Li, J; Lü, L; Rizak, JD; Wang, J; Wang, Z; Wu, J; Xu, L; Yan, T; Yang, L; Yang, S; Zhang, B | 1 |
| Chen, HQ; Huang, Y; Liu, Z; Peng, YP; Qiu, YH | 1 |
| Gao, P; Han, Y; Liu, W; Qiu, S; Yang, L; Zhang, L; Zhong, C; Zhu, S; Zuo, J | 1 |
| Bian, M; Deng, C; Gao, H; Gao, Y; Huang, F; Huang, Y; Sun, F; Yang, S; Yu, M | 1 |
| Hashimoto, T; Ibuki, T; Iwanaga, T; Kishibuchi, R; Kitagawa, H; Mizuguchi, H; Momota, H; Nishihara, S; Onaka, Y; Sado, M; Wada, D; Watanabe, TK; Yamasaki, Y | 1 |
| Caramelli, A; Corsini, GU; Pardini, C; Vaglini, F; Viaggi, C | 1 |
| Cai, L; Fei, J; Gao, H; Huang, F; Huang, Y; Liang, M; Lu, S; Yu, M | 1 |
| Chang, PN; Feng, ZW; Wang, L; Xia, YY; Yang, HJ | 1 |
| Ambrosio, S; Buendía, P; Cano-Jaimez, M; Fariñas, I; Milán, M; Pérez-Sánchez, F | 1 |
| Cao, XB; Huang, JS; Sun, SG; Wang, HC; Wang, T; Xiong, N; Zhang, ZT | 1 |
| Alvira, D; Beas-Zarate, C; Camins, A; de la Torre, AV; Folch, J; Junyent, F; Pallàs, M; Sureda, FX; Verdaguer, E; Yeste-Velasco, M | 1 |
| Maldonado, PD; Medina-Campos, ON; Pedraza-Chaverri, J; Rojas, P; Ruiz-Sánchez, E; Serrano-García, N | 1 |
| Chen, J; Kang, X; Li, X; Liang, Q; Sun, X; Tao, L; Ye, X | 1 |
| Bang, HS; Kim, DG; Kim, SH; Kim, SY; Ko, H; Kwon, HC; Oh, DC; Park, SH; Shin, J | 1 |
| Burdett, TC; Cipriani, S; Desjardins, CA; Schwarzschild, MA; Xu, K; Xu, Y | 1 |
| Cápiro, NL; Dou, J; Han, Y; He, Y; Jia, L; Li, W; Liu, Y; Mao, Z; Pang, Y; Pennell, KD; She, H; Walker, DI; Yang, Q; Yao, L; Zhu, J | 1 |
| Liu, S; Lu, L; Wu, J; Ye, W; Zhang, X | 1 |
| Cory-Slechta, DA; Di Monte, DA; Langston, JW; Manning-Bog, AB; McCormack, AL; Thiffault, C; Thiruchelvam, M | 1 |
| Akaike, A; Honda, K; Ibi, M; Kanki, R; Kihara, T; Nakamizo, T; Nakanishi, M; Sakka, N; Sawada, H; Shimohama, S | 1 |
| Bioulac, B; Fernagut, PO; Ghorayeb, I; Hervier, L; Labattu, B; Tison, F | 1 |
| Mitsumoto, Y; Mori, A; Nakai, M; Watanabe, A | 1 |
| Mohanakumar, KP; Muralikrishnan, D; Samantaray, S | 1 |
| Carrard, G; Friguet, B; Hirsch, EC; Höglinger, GU; Lombès, A; Medja, F; Michel, PP; Ruberg, M | 1 |
| Albers, DS; Beal, MF; Browne, SE; Chirichigno, JW; Gregorio, J; Joh, TH; Lorenzl, S; Shimizu, Y; Shin, DH; Sugama, S; Yang, L | 1 |
| Dryhurst, G; Foster, SB; Han, J; Wrona, MZ | 1 |
| Chuenkova, MV; Pereira, MA | 1 |
| Chang, MY; Choi, CY; Koh, HC; Lee, SH; Lee, YS; Oh, YJ; Roh, E; Shim, JW; Son, H; Studer, L | 1 |
| Conn, KJ; Eisenhauer, PB; Fine, RE; Gao, W; Lan, MS; McKee, A; Ullman, MD; Wells, JM | 1 |
| Bähr, M; Kügler, S; Lingor, P; Schöll, U | 1 |
| Andrews, ZB; Barnstable, CJ; Beal, MF; Elseworth, J; Elsworth, J; Horvath, B; Horvath, TL; Matthews, RT; Roth, RH; Yang, L | 1 |
| Bando, Y; Ishibashi, T; Katayama, T; Matsuo, N; Ogawa, S; Taniguchi, M; Tohyama, M | 1 |
| Gramsbergen, JB; Jakobsen, B; Møller Dall, A; Rosenblad, C; Zimmer, J | 1 |
| Brachet, P; Jaafar, A; Peschanski, M; Robichon, R; Terqui, M | 1 |
| Beal, MF; Calingasan, NY; Chen, J; Cleren, C; Lorenzo, BJ; Starkov, AA | 1 |
| Halliwell, B; Hyun, DH; Jenner, P; Lee, M | 1 |
| Banerjee, R; Chandra, G; Mohanakumar, KP; Nath De, S; Saravanan, KS; Sreetama, S | 1 |
| Hansen, JM; Jones, DP; Miller, GW; Ramachandiran, S; Richardson, JR | 1 |
| Ali, SF; Duhart, HM; Newport, GD; Patterson, TA; Wang, J; Xu, Z | 1 |
| Hashimoto, T; Nagasao, J; Nishi, K; Oyanagi, K; Tsuji, S | 1 |
| Cai, DF; Chen, YP; Gao, JP; Li, WW; Sun, S | 1 |
| Annepu, J; Ravindranath, V | 1 |
| Agani, FH; Chavez, JC; LaManna, JC; Pichiule, P | 1 |
| Lotharius, J; O'Malley, KL | 1 |
| Blanchard, V; Daniel, N; Imperato, A; Moussaoui, S; Obinu, MC; Reibaud, M | 1 |
| Hengerer, B; Spooren, WP; Waldmeier, PC | 1 |
| Ferger, B; Teismann, P | 1 |
| Halliwell, B; Hyun, D; Jenner, P; Lee, M | 1 |
| Helmuth, L | 1 |
| Goloubeva, O; Smeyne, M; Smeyne, RJ | 1 |
| Dawson, TM; Dawson, VL; Guo, X | 1 |
| Baudry, M; Fonck, C | 1 |
| Kubota, S; Obata, T | 1 |
| Cano, J; Machado, A; Santiago, M | 1 |
| Hait, WN; Sonsalla, PK; Staal, RG; Yang, JM | 1 |
| Eto, H; Hayase, N; Kimura, K; Matsubara, K; Mizukami, H; Ogawa, K; Saito, O; Shimizu, K; Shiono, H; Uezono, T | 1 |
| Barc, S; Barrier, L; Fauconneau, B; Page, G; Piriou, A | 1 |
| Benaïssa, M; Fillebeen, C; Mitchell, V; Pierce, A; Ruchoux, MM; Vincent, S | 1 |
| Bai, J; Hattori, I; Nakamura, H; Tanito, M; Yodoi, J | 1 |
| Aoyama, S; Ikeda, K; Kurokawa, M; Kuwana, Y | 1 |
| Obata, T | 1 |
| Fukuoh, A; Hamasaki, N; Iwaasa, M; Iwasaki, H; Kang, D; Ohsato, T; Shinagawa, H; Takamatsu, C; Umeda, S | 1 |
1 review(s) available for 1-methyl-4-phenylpyridinium and Parkinsonian Disorders
| Article | Year |
|---|---|
Role of hydroxyl radical formation in neurotoxicity as revealed by in vivo free radical trapping.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Cells, Cultured; Dopamine; Female; Herbicides; Humans; Hydroxyl Radical; Iron; Male; MPTP Poisoning; Parkinsonian Disorders | 2002 |
91 other study(ies) available for 1-methyl-4-phenylpyridinium and Parkinsonian Disorders
| Article | Year |
|---|---|
Effects of particulate matter and nicotine for the MPP+-induced SH-SY5Y cells: Implication for Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Neurons; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Particulate Matter | 2021 |
Evaluation of efficiency omega 3 fatty acid improves the behavioural phenotype and protects against oxidative stress against MPP+ induces Parkinson's disease in mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Behavior, Animal; Catalase; Fatty Acids, Omega-3; Freezing Reaction, Cataleptic; Frontal Lobe; Glutathione; Glutathione Peroxidase; Levodopa; Male; Mesencephalon; Mice; Open Field Test; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2021 |
Long noncoding RNA NORAD regulates MPP+-induced Parkinson's disease model cells.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Cell Line, Tumor; Humans; Neurons; Oxidative Stress; Parkinsonian Disorders; RNA, Long Noncoding; Signal Transduction | 2019 |
Effects of miR-199a on autophagy by targeting glycogen synthase kinase 3β to activate PTEN/AKT/mTOR signaling in an MPP
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autophagy; Cell Survival; Glycogen Synthase Kinase 3 beta; MicroRNAs; Parkinsonian Disorders; PC12 Cells; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA.
Topics: 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Apoptosis; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; HEK293 Cells; Humans; MicroRNAs; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Up-Regulation | 2020 |
Neuroprotective effects of boron nitride nanoparticles in the experimental Parkinson's disease model against MPP+ induced apoptosis.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Boron Compounds; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Humans; Nanoparticles; Neuroprotective Agents; Parkinsonian Disorders | 2020 |
An acidic heteropolysaccharide from Lycii fructus: Purification, characterization, neurotrophic and neuroprotective activities in vitro.
Topics: 1-Methyl-4-phenylpyridinium; Acids; Animals; Lycium; Neuroprotective Agents; Neurotoxicity Syndromes; Parkinsonian Disorders; PC12 Cells; Plant Extracts; Polysaccharides; Rats | 2020 |
LncRNA HOTAIR Promotes Neuronal Damage Through Facilitating NLRP3 Mediated-Pyroptosis Activation in Parkinson's Disease via Regulation of miR-326/ELAVL1 Axis.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; ELAV-Like Protein 1; Humans; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Neurons; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinsonian Disorders; Pyroptosis; RNA, Long Noncoding | 2021 |
Sigma-1 receptor regulates mitophagy in dopaminergic neurons and contributes to dopaminergic protection.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autophagy-Related Protein-1 Homolog; Cell Line; Dopaminergic Neurons; Gene Knockdown Techniques; Mice; Mitochondria; Mitophagy; Morpholines; Parkinsonian Disorders; Pars Compacta; Phenazocine; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Protein Stability; Protein Transport; Receptors, sigma; Sigma-1 Receptor; Signal Transduction; Substantia Nigra; Ubiquitin; Ubiquitin-Protein Ligases | 2021 |
δ-opioid receptor activation protects against Parkinson's disease-related mitochondrial dysfunction by enhancing PINK1/Parkin-dependent mitophagy.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benzimidazoles; Cell Hypoxia; Gene Knockdown Techniques; Herbicides; Membrane Potential, Mitochondrial; Mitochondria; Mitophagy; Oligopeptides; Parkinsonian Disorders; PC12 Cells; Protein Kinases; Rats; Receptors, Opioid, delta; Superoxides; Ubiquitin-Protein Ligases; Up-Regulation | 2020 |
Febuxostat Inhibits MPP+-Induced Inflammatory Response Through Inhibiting the JNK/NF-κB Pathway in Astrocytes.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Astrocytes; Cells, Cultured; Dose-Response Relationship, Drug; Febuxostat; Gout Suppressants; Inflammation Mediators; MAP Kinase Signaling System; NF-kappa B; Parkinsonian Disorders; Rats; Rats, Wistar | 2021 |
SIRT1 Protects Dopaminergic Neurons in Parkinson's Disease Models via PGC-1α-Mediated Mitochondrial Biogenesis.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neuroprotection; Organelle Biogenesis; Parkinsonian Disorders; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Sirtuin 1 | 2021 |
N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPP
Topics: 1-Methyl-4-phenylpyridinium; Animals; Caffeic Acids; Dopaminergic Neurons; Male; Mice; Mice, Inbred C57BL; Motor Skills Disorders; Nerve Growth Factor; Neuroprotective Agents; Parkinsonian Disorders; PC12 Cells; Protein Precursors; Rats; Rats, Sprague-Dawley | 2018 |
Inhibition of BDNF production by MPP
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Dopaminergic Neurons; Down-Regulation; Humans; Mice, Inbred C57BL; MicroRNAs; Parkinson Disease; Parkinsonian Disorders; Up-Regulation | 2018 |
[Comparison of Parkinson's monkey models induced by unilateral and bilateral intracerebroventricular injections of MPP
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Disease Models, Animal; Haplorhini; Injections, Intraventricular; Male; Parkinsonian Disorders | 2017 |
miR-494-3p modulates the progression of in vitro and in vivo Parkinson's disease models by targeting SIRT3.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation; Humans; Male; Mice, Inbred C57BL; MicroRNAs; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Sirtuin 3 | 2018 |
Long non-coding RNA NEAT1 mediates the toxic of Parkinson's disease induced by MPTP/MPP+ via regulation of gene expression.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Apoptosis; Brain; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Gene Expression Regulation; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; RNA, Long Noncoding; RNA, Small Interfering | 2018 |
Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Differentiation; Cell Survival; Computer Simulation; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Down-Regulation; MicroRNAs; Parkinson Disease; Parkinsonian Disorders; PC12 Cells; Rats; Reactive Oxygen Species; RNA, Messenger; Sirtuin 1; Substantia Nigra; Transcriptome; Up-Regulation | 2018 |
Enteric Neurodegeneration is Mediated Through Independent Neuritic and Somal Mechanisms in Rotenone and MPP+ Toxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; Enteric Nervous System; Female; Insecticides; Mice; MPTP Poisoning; Nerve Degeneration; Neurites; Parkinson Disease, Secondary; Parkinsonian Disorders; Pregnancy; Rotenone | 2018 |
Downregulation of RTN1-C attenuates MPP
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Brain Ischemia; Calcium; Cell Line; Cell Survival; Disease Models, Animal; Down-Regulation; Gene Knockdown Techniques; Homeostasis; Mice; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Protein Isoforms; Receptor, Metabotropic Glutamate 5; RNA, Small Interfering; Signal Transduction | 2019 |
Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Biopterins; Blotting, Western; Colon; Constipation; Disease Models, Animal; Enzyme Inhibitors; Gastric Emptying; Gastrointestinal Motility; Gene Expression Regulation; Heme Oxygenase-1; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; MPTP Poisoning; NF-E2-Related Factor 2; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type I; Parkinson Disease; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2019 |
Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture.
Topics: 1-Methyl-4-phenylpyridinium; Action Potentials; Animals; Animals, Genetically Modified; Bromocriptine; Cholinergic Neurons; Dopamine Agonists; Dopaminergic Neurons; Drosophila melanogaster; Drosophila Proteins; Female; GABAergic Neurons; Male; Nerve Degeneration; Parkinsonian Disorders; Primary Cell Culture; Quinpirole; Receptors, Dopamine D2 | 2013 |
Histone decacetylase inhibitors prevent mitochondrial fragmentation and elicit early neuroprotection against MPP+.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; GTP Phosphohydrolases; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; MPTP Poisoning; Neuroprotective Agents; Parkinsonian Disorders; Rotenone; Uncoupling Agents | 2014 |
Quantitative proteomic analysis reveals mitochondrial protein changes in MPP(+)-induced neuronal cells.
Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; Cell Line, Tumor; Gene Expression Regulation; Humans; Mitochondrial Proteins; Parkinsonian Disorders; Proteomics | 2014 |
Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Electrophysiological Phenomena; KATP Channels; Membrane Potentials; Neural Inhibition; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra | 2014 |
Embryonic stem cells derived neuron transplantation recovery in models of parkinsonism in relation to severity of the disorder in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Basal Ganglia; Behavior, Animal; Brain; Cells, Cultured; Disease Models, Animal; Dopamine; Embryonic Stem Cells; Male; Mice; Motor Activity; Nerve Regeneration; Neural Stem Cells; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats, Sprague-Dawley; Recovery of Function; Severity of Illness Index; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Calcium Signaling; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hippocampus; In Vitro Techniques; Male; Memantine; Membrane Glycoproteins; Memory Disorders; Memory, Long-Term; Mice, Inbred C57BL; Neuronal Plasticity; Parkinsonian Disorders; Protein-Tyrosine Kinases; Signal Transduction; Synapses; Time Factors | 2015 |
UNC-51-like kinase 1 blocks S6k1 phosphorylation contributes to neurodegeneration in Parkinson's disease model in vitro.
Topics: 1-Methyl-4-phenylpyridinium; Amino Acid Substitution; Animals; Autophagy-Related Protein-1 Homolog; Binding Sites; Cell Line; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Gene Knockdown Techniques; Mice; Mutagenesis, Site-Directed; Nerve Degeneration; Parkinsonian Disorders; Phosphorylation; Protein Serine-Threonine Kinases; Recombinant Proteins; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger | 2015 |
The neuroprotective effect of lovastatin on MPP(+)-induced neurotoxicity is not mediated by PON2.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Aryldialkylphosphatase; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Lipid Peroxidation; Lipid Peroxides; Lovastatin; Male; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar; Signal Transduction | 2015 |
Increased 14-3-3 phosphorylation observed in Parkinson's disease reduces neuroprotective potential of 14-3-3 proteins.
Topics: 1-Methyl-4-phenylpyridinium; 14-3-3 Proteins; alpha-Synuclein; Animals; bcl-2-Associated X Protein; Casein Kinases; Cell Line, Tumor; Green Fluorescent Proteins; HEK293 Cells; Hippocampus; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Phosphorylation; Protein Serine-Threonine Kinases; Rotenone; Temporal Lobe | 2015 |
Neuroprotective effects of Eucommia ulmoides Oliv. and its bioactive constituent work via ameliorating the ubiquitin-proteasome system.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Dopamine; Eucommiaceae; Male; Mice; Mice, Inbred C57BL; Motor Disorders; MPTP Poisoning; Neuroprotective Agents; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proteasome Endopeptidase Complex; Ubiquitin | 2015 |
A quantitative approach to developing Parkinsonian monkeys (Macaca fascicularis) with intracerebroventricular 1-methyl-4-phenylpyridinium injections.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Gait; Herbicides; Injections, Intraventricular; Macaca fascicularis; Male; Parkinsonian Disorders; Postural Balance; Severity of Illness Index; Time Factors; Tremor; Tyrosine 3-Monooxygenase | 2015 |
Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP(+)-induced dopaminergic neuronal loss.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Astrocytes; Cells, Cultured; Cerebral Cortex; Dopaminergic Neurons; Inflammation Mediators; MAP Kinase Signaling System; Mesencephalon; Mice; Mice, Inbred C57BL; Microglia; Parkinsonian Disorders; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta1 | 2016 |
MTERF2 contributes to MPP(+)-induced mitochondrial dysfunction and cell damage.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line; DNA-Binding Proteins; Humans; Mitochondria; Mitochondrial Proteins; Neurons; Parkinsonian Disorders; Transcription Factors; Up-Regulation | 2016 |
Expression of Cbl-interacting protein of 85 kDa in MPTP mouse model of Parkinson's disease and 1-methyl-4-phenyl-pyridinium ion-treated dopaminergic SH-SY5Y cells.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Brain; Cell Line; Disease Models, Animal; Gene Expression; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasm Proteins; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-cbl; Tissue Distribution | 2008 |
Protective effect against Parkinson's disease-related insults through the activation of XBP1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcysteine; Animals; Cell Death; Cell Line; Cell Survival; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Dopamine; Endoplasmic Reticulum; Endoribonucleases; Humans; Leupeptins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Serine-Threonine Kinases; Regulatory Factor X Transcription Factors; RNA, Messenger; Signal Transduction; Stress, Physiological; Transcription Factors; X-Box Binding Protein 1 | 2009 |
MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Cytochrome P-450 CYP2E1; Dopamine; Homovanillic Acid; Male; Mice; Mice, Knockout; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Prodrugs; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
Alteration of NRSF expression exacerbating 1-methyl-4-phenyl-pyridinium ion-induced cell death of SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line; Cell Line, Tumor; Cell Survival; Gene Expression Regulation; Herbicides; Humans; Models, Biological; Nerve Degeneration; Neurons; Parkinsonian Disorders; Repressor Proteins; RNA Interference; RNA, Messenger; Substantia Nigra | 2009 |
NF-kappaB mediates MPP+-induced apoptotic cell death in neuroblastoma cells SH-EP1 through JNK and c-Jun/AP-1.
Topics: 1-Methyl-4-phenylpyridinium; Active Transport, Cell Nucleus; Apoptosis; Cell Line, Tumor; DNA-Binding Proteins; Enzyme Inhibitors; Herbicides; Humans; I-kappa B Proteins; JNK Mitogen-Activated Protein Kinases; Nerve Degeneration; Neuroblastoma; NF-kappa B; Parkinsonian Disorders; Proto-Oncogene Proteins c-jun; Transcription Factor AP-1; Transcription Factor RelA | 2010 |
Vulnerability of peripheral catecholaminergic neurons to MPTP is not regulated by alpha-synuclein.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; alpha-Synuclein; Animals; Catecholamines; Cell Death; Cells, Cultured; Ganglia, Sympathetic; Mice; Mice, Mutant Strains; Nerve Degeneration; Neurons; Neurotoxins; Parkinsonian Disorders; Sympathetic Fibers, Postganglionic; Tyrosine 3-Monooxygenase | 2010 |
Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Apoptosis; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Flavonoids; Flow Cytometry; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinsonian Disorders; PC12 Cells; Rats; Reactive Oxygen Species | 2010 |
Prosurvival role of JAK/STAT and Akt signaling pathways in MPP+-induced apoptosis in neurons.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Animals, Newborn; Apoptosis; Cell Survival; Cells, Cultured; Cerebellum; Janus Kinase 2; Mitochondria; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor | 2010 |
S-Allylcysteine, a garlic compound, protects against oxidative stress in 1-methyl-4-phenylpyridinium-induced parkinsonism in mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Cysteine; Garlic; Glutathione Reductase; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase | 2011 |
Salidroside protects against MPP(+)-induced apoptosis in PC12 cells by inhibiting the NO pathway.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Glucosides; Membrane Potential, Mitochondrial; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Oxidative Stress; Parkinsonian Disorders; PC12 Cells; Phenols; Rats; Reactive Oxygen Species; Signal Transduction | 2011 |
Coprismycins A and B, neuroprotective phenylpyridines from the dung beetle-associated bacterium, Streptomyces sp.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Line, Tumor; Cell Survival; Coleoptera; Dopamine; Drug Discovery; Molecular Structure; Neuroblastoma; Neuroprotective Agents; Neurotoxicity Syndromes; Oximes; Parkinsonian Disorders; Pyridines; Streptomyces | 2011 |
Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Astrocytes; Dopaminergic Neurons; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Degeneration; Parkinsonian Disorders; Recombinant Proteins; Tissue Culture Techniques; Urate Oxidase; Uric Acid | 2012 |
Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Behavior, Animal; Cell Line; Dopamine Agents; Dopaminergic Neurons; Herbicides; Male; MEF2 Transcription Factors; Mice; Myogenic Regulatory Factors; Nerve Tissue Proteins; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Substantia Nigra; Tacrine; Tyrosine 3-Monooxygenase | 2012 |
Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Acetylcholinesterase; Alkaloids; Animals; Apoptosis; Cholinesterase Inhibitors; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Regulation, Enzymologic; HEK293 Cells; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinsonian Disorders; PC12 Cells; Rats; Sesquiterpenes; Substantia Nigra | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environmental Exposure; gamma-Aminobutyric Acid; Gliosis; Herbicides; Homovanillic Acid; Humans; Injections, Intraperitoneal; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Risk Factors; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Estradiol protects dopaminergic neurons in a MPP+Parkinson's disease model.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Cell Death; Cells, Cultured; Dopamine; Embryo, Mammalian; Estradiol; Estrogen Receptor beta; Female; JNK Mitogen-Activated Protein Kinases; Mesencephalon; Mitogen-Activated Protein Kinases; Neurons; Parkinsonian Disorders; Pregnancy; Rats; Receptors, Estrogen | 2002 |
A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Forelimb; Herbicides; Intralaminar Thalamic Nuclei; Male; Motor Activity; Motor Cortex; MPTP Poisoning; Multiple System Atrophy; Nerve Degeneration; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2002 |
1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benzimidazoles; Carbocyanines; Coloring Agents; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Fluorometry; Male; Membrane Glycoproteins; Membrane Potentials; Membrane Transport Proteins; Mitochondria; Nerve Tissue Proteins; Oxazines; Oxidation-Reduction; Parkinsonian Disorders; Piperazines; Presynaptic Terminals; Rats; Rats, Wistar; Sodium Cyanide; Synaptosomes; Tyrosine 3-Monooxygenase; Xanthenes | 2003 |
D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Isomerism; Mice; Mice, Inbred BALB C; Monoamine Oxidase; Neostriatum; Neural Pathways; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Selegiline; Substantia Nigra | 2003 |
Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Animals; Cell Death; Cells, Cultured; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Electron Transport Complex I; Enzyme Inhibitors; Mesencephalon; Multienzyme Complexes; NADH, NADPH Oxidoreductases; Neurons; Neurotoxins; Oxidation-Reduction; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Rats; Rats, Wistar; Reactive Oxygen Species; Rotenone; Uncoupling Agents | 2003 |
Minocycline enhances MPTP toxicity to dopaminergic neurons.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-Response Relationship, Drug; Doxycycline; Drug Administration Schedule; Drug Synergism; Gliosis; Male; Mice; Mice, Inbred C57BL; Microglia; Minocycline; Neostriatum; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra; Synaptic Vesicles; Tetracycline | 2003 |
The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Aromatic Amino Acid Decarboxylase Inhibitors; Body Temperature; Chromatography, High Pressure Liquid; Dopa Decarboxylase; Hydroxyindoleacetic Acid; Levodopa; Male; Mannitol; Microdialysis; Neostriatum; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Salicylates; Serotonin; Time Factors | 2003 |
PDNF, a human parasite-derived mimic of neurotrophic factors, prevents caspase activation, free radical formation, and death of dopaminergic cells exposed to the Parkinsonism-inducing neurotoxin MPP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Caspase 3; Caspases; Cell Death; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Free Radicals; Humans; MAP Kinase Signaling System; Molecular Mimicry; Nerve Growth Factors; Neuraminidase; Neurons; Parkinsonian Disorders; PC12 Cells; Rats; Trypanosoma cruzi | 2003 |
Enhanced in vitro midbrain dopamine neuron differentiation, dopaminergic function, neurite outgrowth, and 1-methyl-4-phenylpyridium resistance in mouse embryonic stem cells overexpressing Bcl-XL.
Topics: 1-Methyl-4-phenylpyridinium; Animals; bcl-X Protein; Cell Differentiation; Cell Survival; Cells, Cultured; Dopamine; Drug Resistance; Gene Transfer Techniques; Graft Survival; Mesencephalon; Mice; Neurites; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Serotonin; Stem Cell Transplantation; Stem Cells | 2004 |
Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Aged; Aged, 80 and over; Analysis of Variance; Animals; Blotting, Northern; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Dopamine; Female; Gene Expression Regulation; Humans; Immunohistochemistry; Lewy Bodies; Male; Middle Aged; Neuroblastoma; Nuclear Proteins; Parkinsonian Disorders; Postmortem Changes; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Tretinoin | 2004 |
Functional applications of novel Semliki Forest virus vectors are limited by vector toxicity in cultures of primary neurons in vitro and in the substantia nigra in vivo.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; bcl-X Protein; Cells, Cultured; Disease Models, Animal; Dopamine; Female; Gene Expression Regulation, Viral; Gene Transfer Techniques; Genetic Vectors; Nerve Degeneration; Neurons; Parkinsonian Disorders; Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Wistar; Semliki forest virus; Substantia Nigra; Transduction, Genetic; Transgenes; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; Immunohistochemistry; Ion Channels; Male; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Mitochondria; Mitochondrial Proteins; Oxygen Consumption; Parkinsonian Disorders; Reactive Oxygen Species; Substantia Nigra; Uncoupling Protein 2 | 2005 |
RA410/Sly1 suppresses MPP+ and 6-hydroxydopamine-induced cell death in SH-SY5Y cells.
Topics: 1-Methyl-4-phenylpyridinium; Adaptation, Physiological; Animals; Apoptosis; Carrier Proteins; Caspases; Cell Survival; Dopamine; Endoplasmic Reticulum; Humans; Immediate-Early Proteins; Microscopy, Electron, Transmission; Munc18 Proteins; Nerve Degeneration; Neurons; Neurotoxins; Oligonucleotides, Antisense; Oxidative Stress; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra; Transfection; Tumor Cells, Cultured | 2005 |
Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Differentiation; Cell Proliferation; Cell Size; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glial Cell Line-Derived Neurotrophic Factor; Mice; Mice, Inbred C57BL; Nerve Degeneration; Nerve Growth Factors; Neurons; Neuroprotective Agents; Neurotoxins; Organ Culture Techniques; Parkinsonian Disorders; Recovery of Function; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Pig xenografts to the immunocompetent rat brain: Survival rates using distinct neurotoxic lesions in the nigrostriatal pathway and two rat strains.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain Tissue Transplantation; Cell Size; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Fetal Tissue Transplantation; Graft Survival; Male; Neural Pathways; Neurons; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Quinolinic Acid; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Species Specificity; Substantia Nigra; Swine; Time Factors; Transplantation, Heterologous | 2005 |
Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Calcium; Calcium Signaling; Disease Models, Animal; Dopamine; Electron Transport Complex I; Histamine H1 Antagonists; Male; Membrane Potentials; Mice; Mitochondria; Mitochondrial Membranes; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Promethazine; Substantia Nigra | 2005 |
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Aldehydes; Apoptosis; Cell Death; Cell Line, Tumor; Drug Resistance; Enzyme Inhibitors; Genetic Predisposition to Disease; Glutamic Acid; Guanine; Humans; Hydrogen Peroxide; Mutation; Nerve Degeneration; Neurons; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Substantia Nigra; Tyrosine; Ubiquitin-Protein Ligases | 2005 |
Intrastriatal infusion of the Parkinsonian neurotoxin, MPP(+), induces damage of striatal cell nuclei in Sprague-Dawley rats.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcholine; Animals; Atrophy; Cell Nucleus; Cholinergic Fibers; Coloring Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Herbicides; Male; Microscopy, Electron, Transmission; Nerve Degeneration; Neurons; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2006 |
Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Herbicides; Humans; Insecticides; JNK Mitogen-Activated Protein Kinases; Mitochondrial Proteins; Neurons; Oxidation-Reduction; Paraquat; Parkinsonian Disorders; Rotenone; Thioredoxins; Transfection | 2007 |
Comparison of the time courses of selective gene expression and dopaminergic depletion induced by MPP+ in MN9D cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carrier Proteins; Cell Line; Disease Progression; DNA-Binding Proteins; Dopamine; Down-Regulation; Gene Expression Regulation; Herbicides; Hypoxia-Inducible Factor-Proline Dioxygenases; Immediate-Early Proteins; Isoenzymes; L-Lactate Dehydrogenase; Membrane Proteins; Mice; Mitochondrial Proteins; Neurons; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Substantia Nigra; Thioredoxins; Time Factors | 2008 |
Magnesium exerts both preventive and ameliorating effects in an in vitro rat Parkinson disease model involving 1-methyl-4-phenylpyridinium (MPP+) toxicity in dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; Dopamine; Immunohistochemistry; In Vitro Techniques; Magnesium; Microscopy, Immunoelectron; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Rats; Tyrosine 3-Monooxygenase | 2008 |
Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: implication for immunosuppressive therapy in Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Biomarkers; CD11b Antigen; Cell Count; Cell Survival; Disability Evaluation; Diterpenes; Dopamine; Encephalitis; Epoxy Compounds; Gliosis; Herbicides; Immunosuppression Therapy; Immunosuppressive Agents; Male; Microglia; Neurons; Parkinsonian Disorders; Phenanthrenes; Rats; Rats, Sprague-Dawley; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase | 2008 |
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced complex I inhibition is reversed by disulfide reductant, dithiothreitol in mouse brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dithiothreitol; Electron Transport Complex I; Glutathione; Male; Mice; Mitochondria; NADH, NADPH Oxidoreductases; Nerve Degeneration; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Parkinsonian Disorders | 2000 |
The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease Models, Animal; DNA; DNA-Binding Proteins; DNA, Mitochondrial; Electron Transport; Electron Transport Complex I; Gene Expression Regulation; Humans; Hybrid Cells; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred C57BL; Mitochondria; NADH, NADPH Oxidoreductases; Neostriatum; Nuclear Proteins; Oxygen; Parkinsonian Disorders; Primates; Protein Binding; Succinic Acid; Transcription Factors; Tumor Cells, Cultured | 2000 |
The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Cells, Cultured; Dopamine; Kinetics; Mesencephalon; Mice; Neurons; Oxidation-Reduction; Parkinsonian Disorders; Reactive Oxygen Species; Rotenone | 2000 |
The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Azoles; Behavior, Animal; Blood Proteins; Callithrix; Caudate Nucleus; Disease Models, Animal; Female; Free Radicals; Glutathione Peroxidase; Herbicides; Isoindoles; Locomotion; Male; Mitochondria; Molecular Mimicry; Neurons; Neuroprotective Agents; Organoselenium Compounds; Parkinsonian Disorders; PC12 Cells; Rats; Rats, Sprague-Dawley; Substantia Nigra; Tritium | 2000 |
CGP 3466 protects dopaminergic neurons in lesion models of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Brain; Cell Culture Techniques; Cell Death; Disease Models, Animal; Dopamine; Female; Liver; Mesencephalon; Mice; Mice, Inbred C57BL; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxepins; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Selegiline; Substantia Nigra; Tritium; Tyrosine 3-Monooxygenase | 2000 |
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Count; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Dopamine; Homovanillic Acid; Isoenzymes; Male; Meloxicam; Membrane Proteins; Mice; Mice, Inbred C57BL; Motor Activity; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Prostaglandin-Endoperoxide Synthases; Substantia Nigra; Thiazines; Thiazoles; Tyrosine 3-Monooxygenase | 2001 |
Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult.
Topics: 1-Methyl-4-phenylpyridinium; Aldehydes; alpha-Synuclein; Cell Division; Cell Line; Cell Survival; Clone Cells; Culture Media, Serum-Free; Enzyme Inhibitors; Gene Expression; Glutathione; Guanine; Humans; Hydrogen Peroxide; Ketones; Lipid Peroxidation; Mitochondria; Mutation; Nerve Tissue Proteins; Neuroblastoma; Oxidants; Oxidative Stress; Parkinsonian Disorders; Synucleins; Teratocarcinoma; Transfection; Tyrosine | 2001 |
Neuroscience. Pesticide causes Parkinson's in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain; Disease Models, Animal; Dopamine; Electron Transport Complex I; Free Radicals; Humans; Insecticides; Lewy Bodies; Mitochondria; NADH, NADPH Oxidoreductases; Neurons; Parkinson Disease; Parkinsonian Disorders; Rats; Risk Factors; Rotenone; Uncoupling Agents | 2000 |
Strain-dependent susceptibility to MPTP and MPP(+)-induced parkinsonism is determined by glia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Death; Cells, Cultured; Dopamine; Dopamine Agents; Herbicides; Mice; Mice, Inbred C57BL; Neuroglia; Parkinsonian Disorders; Reactive Oxygen Species; Species Specificity; Substantia Nigra | 2001 |
Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Brain Injuries; Cells, Cultured; Dopamine; Immunophilins; Immunosuppressive Agents; Ligands; Mesencephalon; Mice; Mice, Knockout; Nerve Degeneration; Nerve Regeneration; Neurons; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Pyrrolidines; Rats; Rats, Sprague-Dawley; Tacrolimus; Tacrolimus Binding Protein 1A; Tyrosine 3-Monooxygenase | 2001 |
Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Differentiation; Cell Survival; Dopamine; Dopamine Agents; Drug Interactions; Free Radical Scavengers; Herbicides; Lipid Peroxidation; NAD; Nerve Growth Factor; Neurons; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats; Reactive Oxygen Species; Substantia Nigra; Tritium | 2001 |
Protective effect of tamoxifen on 1-methyl-4-phenylpyridine-induced hydroxyl radical generation in the rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Hydroxyl Radical; Male; Microdialysis; Neostriatum; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
Validity of a quantitative technique to study striatal dopaminergic neurodegeneration by in vivo microdialysis.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Chromatography, High Pressure Liquid; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Immunohistochemistry; Male; Microdialysis; Neostriatum; Nerve Degeneration; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Wistar; Reproducibility of Results; Statistics as Topic; Time Factors; Tyrosine 3-Monooxygenase | 2001 |
Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Calcium Channel Blockers; Cell Survival; Dopamine; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Immunosuppressive Agents; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Knockout; Neuropeptides; Parkinsonian Disorders; Subcellular Fractions; Tumor Cells, Cultured; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2001 |
Glutamate is not involved in the MPP+-induced dopamine overflow in the striatum of freely moving C57BL/6 mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Extracellular Space; Glutamic Acid; Herbicides; Male; Mice; Mice, Inbred C57BL; Microdialysis; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 2001 |
Impairment of the neuronal dopamine transporter activity in MPP(+)-treated rat was not prevented by treatments with nitric oxide synthase or poly(ADP-ribose) polymerase inhibitors.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Interactions; Enzyme Inhibitors; Male; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Nerve Tissue Proteins; Neurons; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Parkinsonian Disorders; Poly Adenosine Diphosphate Ribose; Presynaptic Terminals; Radioligand Assay; Rats; Rats, Wistar; Substantia Nigra; Synaptosomes; Tritium | 2001 |
Lactoferrin is synthesized by activated microglia in the human substantia nigra and its synthesis by the human microglial CHME cell line is upregulated by tumor necrosis factor alpha or 1-methyl-4-phenylpyridinium treatment.
Topics: 1-Methyl-4-phenylpyridinium; Aged; Antineoplastic Agents; Cell Line, Transformed; Encephalitis; Female; Gene Expression; Humans; Lactoferrin; Male; Microglia; Oxidative Stress; Parkinsonian Disorders; Polymerase Chain Reaction; RNA, Messenger; Substantia Nigra; Tumor Necrosis Factor-alpha | 2001 |
Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Anti-Ulcer Agents; Cell Survival; Diterpenes; Dose-Response Relationship, Drug; Drug Interactions; HSP70 Heat-Shock Proteins; L-Lactate Dehydrogenase; Neurons; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; PC12 Cells; Rats; Thioredoxins | 2002 |
Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Antineoplastic Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Gliosis; Herbicides; Male; Nerve Degeneration; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Sympatholytics; Tritium | 2002 |
1-Methyl-4-phenylpyridinium ion, a toxin that can cause parkinsonism, alters branched structures of DNA.
Topics: 1-Methyl-4-phenylpyridinium; Bacterial Proteins; DNA Helicases; DNA, Mitochondrial; DNA, Superhelical; Dose-Response Relationship, Drug; Escherichia coli Proteins; HeLa Cells; Humans; Intercalating Agents; Magnesium; Nucleic Acid Conformation; Parkinsonian Disorders | 2002 |